Market Place
Sourcing Support
Dyadic Provides Update & Attend 43rd J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Dyadic Receives $3M Grant for Monoclonal Antibodies for RSV
21 Nov 2024 //
GLOBENEWSWIRE
Dyadic Announces Q3 2024 Financial Results & Strategic Progress
12 Nov 2024 //
GLOBENEWSWIRE
Dyadic to Report Q3 2024 Financial Results on Nov 12, 2024
04 Nov 2024 //
GLOBENEWSWIRE
Dyadic Expands Global Presence At Key Industry Events
09 Oct 2024 //
GLOBENEWSWIRE
Dyadic Updates On Alternative Proteins Business
23 Sep 2024 //
GLOBENEWSWIRE
Dyadic Announces Q2 2024 Results And Recent Company Progress
13 Aug 2024 //
GLOBENEWSWIRE
Dyadic To Report Q2 2024 Results On August 13
30 Jul 2024 //
GLOBENEWSWIRE
Dyadic And Proliant Announce Recombinant Albumin Development Partnership
28 Jun 2024 //
GLOBENEWSWIRE
Dyadic to Attend Industry Events in June
30 May 2024 //
GLOBENEWSWIRE
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes
11 Mar 2024 //
GLOBENEWSWIRE
Dyadic to Attend Industry Events in March
01 Mar 2024 //
GLOBENEWSWIRE
Dyadic Advances Collaboration with IIBR Targeting Bio-Threats
23 Feb 2024 //
GLOBENEWSWIRE
Dyadic Advances Collaboration with IIBR Targeting Bio-Threats
21 Feb 2024 //
GLOBENEWSWIRE
Dyadic Announces R&D Agreement with Global Biopharmaceutical Company
06 Feb 2024 //
GLOBENEWSWIRE
Dyadic Announces Results from iPhase 1 Trial for Fungal-Based Vaccine Candidate
29 Nov 2023 //
GLOBENEWSWIRE
Dyadic to Present at Industry Events in November
30 Oct 2023 //
GLOBENEWSWIRE
Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 Oct 2023 //
GLOBENEWSWIRE
Dyadic™s C1 Platform Selected by the Vaccine and Immunotherapy Center
05 Oct 2023 //
GLOBENEWSWIRE
Dyadic to Present at Industry and Investor Events in October
29 Sep 2023 //
GLOBENEWSWIRE
Dyadic to Present at BioProcess International
12 Sep 2023 //
GLOBENEWSWIRE
Dyadic Announces Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Dyadic to Report Q2 2023 Financial Results on Wednesday, August 9, 2023
26 Jul 2023 //
GLOBENEWSWIRE
Dyadic Provides Phase 1 Trial Update for RBD Vaccine Candidate
24 Jul 2023 //
GLOBENEWSWIRE
Dyadic to Participate at Upcoming Events in June
01 Jun 2023 //
GLOBENEWSWIRE
Dyadic Announces Expanded Agreement to Develop Vaccines
12 Apr 2023 //
GLOBENEWSWIRE
Dyadic to Present at World Vaccine Congress Washington 2023
30 Mar 2023 //
GLOBENEWSWIRE
Dyadic Reports 2022 Year End Results and Recent Company Progress
29 Mar 2023 //
GLOBENEWSWIRE
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
15 Mar 2023 //
GLOBENEWSWIRE
Dyadic Provides Phase 1 Trial Update for its DYAI-100 Vaccine Candidate
07 Mar 2023 //
GLOBENEWSWIRE
Dyadic to Participate in Two Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
Dyadic Announces Initiation of Dosing of First-In-Human PI Trial for DYAI-100
24 Jan 2023 //
GLOBENEWSWIRE
Dyadic Announces Sale of Equity Interest in Alphazyme
19 Jan 2023 //
GLOBENEWSWIRE
Dyadic`s DYAI-100 COVID-19 Vaccine Study Published in Peer-Reviewed Journal
14 Dec 2022 //
GLOBENEWSWIRE
Dyadic Reports 3Q 2022 Financial Results and Highlights Recent Developments
10 Nov 2022 //
GLOBENEWSWIRE
Dyadic Receives Regulatory Approval to Initiate PI Trial for DYAI-100
27 Oct 2022 //
GLOBENEWSWIRE
Dyadic to Report Q3 2022 Financial Results on Thursday, November 10, 2022
27 Oct 2022 //
GLOBENEWSWIRE
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe
04 Oct 2022 //
GLOBENEWSWIRE
Dyadic Updates Market on Recent Scientific Achievements
13 Sep 2022 //
GLOBENEWSWIRE
Dyadic Reports Q2 Financial Results and Highlights Recent Company Developments
10 Aug 2022 //
GLOBENEWSWIRE
Dyadic to Report Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL
05 Jul 2022 //
GLOBENEWSWIRE
Dyadic to Participate in Three Upcoming Industry Events
09 Jun 2022 //
GLOBENEWSWIRE
Dyadic to Present at 2022 Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Dyadic to Present at H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
Dyadic Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Dyadic Announces Research, License and Collaboration for Animal Free Ingredients
11 May 2022 //
GLOBENEWSWIRE
Dyadic Announces Successful Toxicology Data Published in Toxicologic Pathology
09 May 2022 //
GLOBENEWSWIRE
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
28 Apr 2022 //
GLOBENEWSWIRE
Dyadic International to Present at Upcoming Scientific Medical Meetings
04 Apr 2022 //
GLOBENEWSWIRE
Dyadic Reports 2021 Year End Results and Recent Company Progress
29 Mar 2022 //
GLOBENEWSWIRE
Freeline Closes $26.1 M Registered Direct Offering of American Depositary Shares
15 Mar 2022 //
GLOBENEWSWIRE
Dyadic and Phibro Animal Health Announce Exclusive License Agreement
10 Feb 2022 //
GLOBENEWSWIRE
Dyadic’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
07 Feb 2022 //
GLOBENEWSWIRE
Dyadic Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
ACCESSWIRE
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES”
28 Jun 2021 //
GLOBENEWSWIRE
Dyadic`s DYAI-100 Advancing Towards Human Clinical Trial
18 Mar 2021 //
GLOBENEWSWIRE
